Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest NeoGenomics Inc. Stories

2014-04-03 12:28:42

FT. MYERS, Fla., April 3, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2014 financial results on Wednesday April 23, 2014. The Company has scheduled a web-cast and conference call to discuss their Q1 2014 results on Wednesday April 23, 2014 at 11:00 AM EDT. Interested investors should dial (877) 407-0782 (domestic) and (201) 689-8567 (international) at least five minutes prior to the call and ask for Conference ID...

2014-03-18 08:31:43

Company is First to Offer Plasma-Based Next Generation Sequencing Tests FORT MYERS, Fla., March 18, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched the first two of a series of next generation cancer profiling tests. These tests are designed for profiling myelodysplastic syndrome (MDS) and solid tumor cancers. Additional cancer-type specific next...

2014-02-19 08:30:32

Company Set to Launch Next Generation Sequencing Services in March 2014 FT. MEYERS, Fla., Feb. 19, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2013. Fourth Quarter 2013 Highlights: -- Revenue growth of 23% -- Test volume growth of 28% -- Gross Profit Margin of 50.0% versus 43.2% last year -- Adjusted EBITDA((1)) growth of 90% --...

2014-01-30 08:30:59

FT. MYERS, Fla., Jan. 30, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor. The 22 categories of tumors covered in this series of...

2014-01-17 16:23:34

FORT MYERS, Fla., Jan. 17, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter 2013 and full year 2013 financial results on Wednesday, February 19, 2014. The Company has scheduled a web-cast and conference call to discuss their Q4 2013 and full year 2013 results on Wednesday, February 19, 2014 at 11:00 AM EST. Interested investors should dial (877) 407-8035 (domestic) and (201) 689-8035 (international) at least five...

2014-01-07 08:30:05

FT. MYERS, Fla., Jan. 7, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology (ASH) last month. Since then, findings...

2013-11-18 08:27:54

Alliance provides clients with seamless global specialty testing services critical to oncology clinical trials PRINCETON, N.J. and FT. MYERS, Fla., Nov. 18, 2013 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, and NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology-focused genetics testing services, today announced a strategic collaboration to jointly provide anatomic pathology and...

2013-10-23 08:29:19

FT. MYERS, Fla., Oct. 23, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2013. Third Quarter 2013 Highlights: -- Revenue growth of 18.9% -- Test volume growth of 19.1% -- Gross Profit Margin of 48.4% versus 41.5% last year -- Adjusted EBITDA((1)) growth of 157% -- Net Income of $0.02 per share versus a loss of $0.02 last year Revenue for the...

2013-10-07 16:24:46

FT. MYERS, Fla., Oct. 7, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its third quarter 2013 financial results on Wednesday, October 23, 2013. The Company has scheduled a web-cast and conference call to discuss their Q3 2013 results on Wednesday, October 23, 2013 at 11:00 AM EDT. Interested investors should dial (877) 407-8035 (domestic) and (201) 689-8035 (international) at least five minutes prior to the call and ask for Conference...

2013-09-26 08:26:52

FT. MYERS, Fla., Sept. 26, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it was revising upward its previously issued guidance for Quarter 3, 2013. The Company now expects revenue of approximately $16.6 - $16.9 million and earnings per share of $0.01 - $0.02 in the third quarter. The Company had originally guided to revenue of $15.8 - $16.4 million and earnings per share of $0.00 - $0.01 on July 31, 2013. Doug VanOort, the Company's Chairman and...